InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $1.760 0.055 (3.03%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$345 Application for quotation of securities - RAC 26 Feb 2026 10:57AM $2.400 $1.760 fallen by 26.67%
$345 Appendix 3Y - Dr Daniel Tillett 19 Feb 2026 1:48PM $2.190 $1.760 fallen by 19.63%
$345 Application for quotation of securities - RAC 19 Feb 2026 1:43PM $2.190 $1.760 fallen by 19.63%
$345 Appendix 3Y - Dr Daniel Tillett 16 Feb 2026 11:20AM $2.070 $1.760 fallen by 14.98%
$345 Application for quotation of securities - RAC 12 Feb 2026 2:02PM $2.280 $1.760 fallen by 22.81%
$345 Racura Develops Novel Cardioprotection Blood Test 11 Feb 2026 9:09AM $2.450 $1.760 fallen by 28.16%
$345 Notification of buy-back - RAC 6 Feb 2026 9:09AM $2.300 $1.760 fallen by 23.48%
$345 Capital Structure Update 6 Feb 2026 9:08AM $2.300 $1.760 fallen by 23.48%
$345 Application for quotation of securities - RAC 5 Feb 2026 2:42PM $2.310 $1.760 fallen by 23.81%
$345 Application for quotation of securities - RAC 29 Jan 2026 2:25PM $2.230 $1.760 fallen by 21.08%
$345 December 2025 Quarterly Activity Report and Appendix 4C 29 Jan 2026 9:17AM $2.420 $1.760 fallen by 27.27%
$345 Appendix 3Y - Dr Daniel Tillett 22 Jan 2026 3:24PM $2.730 $1.760 fallen by 35.53%
$345 Application for quotation of securities - RAC 22 Jan 2026 3:18PM $2.740 $1.760 fallen by 35.77%
$345 Application for quotation of securities - RAC 15 Jan 2026 3:11PM $2.860 $1.760 fallen by 38.46%
$345 Racura Oncology Emory University Collaboration 14 Jan 2026 9:04AM $2.880 $1.760 fallen by 38.89%
$345 Application for quotation of securities - RAC 8 Jan 2026 2:25PM $2.820 $1.760 fallen by 37.59%
$345 Application for quotation of securities - RAC 2 Jan 2026 1:38PM $2.910 $1.760 fallen by 39.52%
$345 Racura Oncology Appoints BDD for HARNESS-1 Trial 24 Dec 2025 9:24AM $2.790 $1.760 fallen by 36.92%
$345 Application for quotation of securities - RAC 23 Dec 2025 2:13PM $2.790 $1.760 fallen by 36.92%
$345 Appendix 3Y - Dr Daniel Tillett 18 Dec 2025 4:42PM $2.540 $1.760 fallen by 30.71%
$345 Application for quotation of securities - RAC 18 Dec 2025 3:18PM $2.540 $1.760 fallen by 30.71%
$345 Cleansing Notice 11 Dec 2025 12:42PM $2.590 $1.760 fallen by 32.05%
$345 Application for quotation of securities - RAC 11 Dec 2025 12:38PM $2.590 $1.760 fallen by 32.05%
$345 Application for quotation of securities - RAC 11 Dec 2025 11:03AM $2.640 $1.760 fallen by 33.33%
$345 Change of Company Name 9 Dec 2025 4:32PM $2.780 $1.760 fallen by 36.69%

76 - 100 of 1000 results

Page 4 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.